JF
ENTA icon

Jump Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

Jump Financial’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,900
Closed -$219K – 2025
2025
Q4 		$219K Buy
+13,900
New +$177K ﹤0.01% 1699
2024
Q4 		– Sell
-16,400
Closed -$170K – 1756
2024
Q3 		$170K Buy
16,400
+1,200
+8% +$15.7K ﹤0.01% 1489
2024
Q2 		$197K Buy
+15,200
New +$205K ﹤0.01% 1568
2024
Q1 		– Sell
-31,868
Closed -$300K – 1999
2023
Q4 		$300K Sell
31,868
-24,768
-44% -$231K 0.01% 1337
2023
Q3 		$633K Buy
56,636
+16,608
+41% +$267K 0.02% 891
2023
Q2 		$857K Buy
40,028
+24,060
+151% +$709K 0.03% 759
2023
Q1 		$646K Buy
15,968
+7,748
+94% +$370K 0.03% 779
2022
Q4 		$382K Sell
8,220
-1,492
-15% -$68K 0.02% 900
2022
Q3 		$504K Sell
9,712
-10,088
-51% -$589K 0.02% 899
2022
Q2 		$936K Buy
+19,800
New +$1.07M 0.04% 603
2021
Q3 		– Sell
-8,400
Closed -$370K – 1199
2021
Q2 		$370K Buy
+8,400
New +$411K 0.04% 585
2021
Q1 		– Sell
-6,694
Closed -$282K – 1025
2020
Q4 		$282K Buy
+6,694
New +$294K 0.05% 622

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jump Financial's ENTA Position: Q1 2026 in Review

Jump Financial sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 13,900 shares — an estimated $219K sold.

Jump Financial first reported a position in ENTA in Q4 2020 and held it in 12 quarters. The position peaked at $936K in Q2 2022. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Jump Financial reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jump Financial sold 13,900 Enanta Pharmaceuticals shares in Q1 2026, an estimated $219K.
  • Jump Financial first reported a position in Enanta Pharmaceuticals in Q4 2020 and held it in 12 quarters.
  • Jump Financial's Enanta Pharmaceuticals position peaked at $936K in Q2 2022.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.